Overview

A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, phase III study to evaluate the efficacy and safety of HCP2102 in patients with essential hypertension
Phase:
Phase 3
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited